Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.

@article{Benza2008SitaxsentanFT,
  title={Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.},
  author={Raymond L. Benza and Robyn J. Barst and Nazzereno Gali{\`e} and Adaani Frost and Reda E. Girgis and Kristin B. Highland and Charlie Strange and Carol Mary Black and David B. Badesch and Lewis Rubin and Thomas R. Fleming and Robert Naeije},
  journal={Chest},
  year={2008},
  volume={134 4},
  pages={775-82}
}
BACKGROUND Despite advances in the management of pulmonary arterial hypertension (PAH), the mortality rate remains excessive. Long-term efficacy evaluations are needed to guide therapeutic management. The purpose of this study is to present 1-year observational data with two endothelin antagonists, sitaxsentan and bosentan, in a prospective, open-label study. METHODS The present study was a prospective, international, multicenter, randomized, open-label extension of the Sitaxsentan To Relieve… CONTINUE READING
35 Citations
20 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…